Related Experiment Video
Updated: May 27, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Optimal antiviral switching to minimize resistance risk in HIV therapy
Rutao Luo1, Michael J Piovoso, Javier Martinez-Picado
1Department of Electrical and Computer Engineering, University of Delaware, Newark, Delaware, United States of America.
Abstract:
The development of resistant strains of HIV is the most significant barrier to effective long-term treatment of HIV infection. The most common causes of resistance development are patient noncompliance and pre-existence of resistant strains. In this paper, methods of antiviral regimen switching are developed that minimize the risk of pre-existing resistant virus emerging during therapy switches necessitated by virological failure. Two distinct cases are considered; a single previous virological failure and multiple virological failures. These methods use optimal control approaches on experimentally verified mathematical models of HIV strain competition and statistical models of resistance risk. It is shown that, theoretically, order-of-magnitude reduction in risk can be achieved, and multiple previous virological failures enable greater success of these methods in reducing the risk of subsequent treatment failures.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Retroviruses
Inhibitors of Virion Maturation and Assembly
Size and Structure of Viral Genomes

